It’s been an intense but very productive 42nd European Society of Human Reproduction and Embryology (ESHRE) Congress – the world’s largest gathering of professionals in reproductive medicine and embryology, held at Excel London. 🌸 So many great conversations, catch-ups and new connections forged: all united by a shared mission to improve fertility outcomes in the …

FREEDOM trial reaches 100% patient consent. Calla Lily Clinical Care is pleased to share an important milestone in our NIHR funded FREEDOM clinical trial. In less than three months since recruitment began, FREEDOM has passed its safety stopping rule, and all target patient participants are now consented. More than half of total participants have also …

We’re delighted to be featured by Technology Networks in this interview with our co-founders, Dr Lara Zibners and Thang Vo-Ta, about our Callavid® intravaginal drug delivery platform. Our first focus is progesterone delivery for threatened miscarriage and IVF– areas where the clinical need is significant, but where the patient experience has too often been overlooked. …

With our FREEDOM clinical trial making exciting progress– now 60% recruited — we are delighted to start receiving national media coverage for this important step towards a more patient-centric option for women suffering from threatened miscarriage. A big thank you to the Daily Mail for featuring Callavid® and our University Hospitals Coventry and Warwickshire (UHCW) …

Our colleagues Ewa Radziwon and Shaun Knights had a very productive few days at INDEX Nonwovens INDEX™26 in #Geneva, hosted by EDANA, the voice of nonwovens 🇨🇭 As the world’s leading nonwovens exhibition, it was important for Calla Lily Clinical Care to attend again: reconnecting with existing suppliers, meeting potential new partners, and exploring exciting …

It was recently World Clinical Trials Day, and our co-founder Lara took part in a special event hosted by SökerData and Covington & Burling LLP: 🔬 “Innovation in Action: Successful Women’s Clinical Trial Case Studies” 🧪 Lara shared the context, design and exciting early progress of our ongoing FREEDOM clinical trial evaluating Callavid® for threatened …

About 18 months after taking part in the inaugural Barclays Demo Day, it was great to return to Barclays’ Canary Wharf HQ to present Calla Lily Clinical Care again. Last time, we were pitching our ambitious plans to transform drug delivery for women. This time, those plans are bolder than ever– but now backed by …

Original article here Calla Lily Clinical Care begins dosing in trial of intravaginal platform for threatened miscarriage by John Pinching | 7th May 2026 | News Nihr‑funded phase 2 study to assess progesterone delivery using Callavid device Calla Lily Clinical Care has dosed the first patients in its Freedom clinical trial, a nihr‑funded study evaluating the company’s Callavid …

CLCC was delighted to have taken part in the Cleveland Clinic Global Women’s Health Forum, co-hosted by the Women’s Alzheimer’s Movement and Maria Shriver. It was an inspiring gathering of voices across medicine, research, advocacy, and innovation, with important conversations spanning heart and brain health, strength, mental wellbeing, financial health, and more. 💪 Our co-founder …

Original article here by Geri Stengel   Picture the pitch room. Dr. Lara Zibners has a question for the male-majority audience. “How many of you have put medication up your nose?” A few hands go up. Then: “…besides cocaine.” Laughter. Then the turn: if nasal drugs leaked the way vaginal drugs do, one of them …